vs
Lakeside Holding Ltd（LSH）与礼来（RNA）财务数据对比。点击上方公司名可切换其他公司
礼来的季度营收约是Lakeside Holding Ltd的1.8倍（$12.5M vs $7.0M），Lakeside Holding Ltd净利率更高（-22.6% vs -1398.3%，领先1375.7%），礼来同比增速更快（434.0% vs 95.0%）
莱克赛德出版社是位于美国芝加哥的出版品牌，由RR唐纳利公司运营。该社除了出版高品质书籍外，还承印邮购目录、电话号码簿、百科全书与广告宣传品，最为人熟知的是为芝加哥卡克斯顿俱乐部出版的高端版本，以及经典重印丛书《莱克赛德经典》。
礼来是总部位于美国印第安纳州印第安纳波利斯的跨国制药企业，在18个国家设有办事处，产品销往全球约125个国家。公司由美国内战时期联邦军退伍军人、药剂师伊莱·礼来于1876年创立，品牌名即取自创始人姓名。
LSH vs RNA — 直观对比
营收规模更大
RNA
是对方的1.8倍
$7.0M
营收增速更快
RNA
高出339.0%
95.0%
净利率更高
LSH
高出1375.7%
-1398.3%
损益表 — Q4 FY2025 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $7.0M | $12.5M |
| 净利润 | $-1.6M | $-174.4M |
| 毛利率 | 27.2% | — |
| 营业利润率 | -21.3% | -1513.5% |
| 净利率 | -22.6% | -1398.3% |
| 营收同比 | 95.0% | 434.0% |
| 净利润同比 | 18.7% | -117.0% |
| 每股收益（稀释后） | $-0.08 | $-1.27 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LSHRNA
| Q4 25 | $7.0M | — | ||
| Q3 25 | $6.1M | $12.5M | ||
| Q2 25 | $6.3M | $3.8M | ||
| Q1 25 | $3.8M | $1.6M | ||
| Q4 24 | $3.6M | $3.0M | ||
| Q3 24 | $4.1M | $2.3M | ||
| Q2 24 | — | $2.0M | ||
| Q1 24 | — | $3.5M |
净利润LSHRNA
| Q4 25 | $-1.6M | — | ||
| Q3 25 | $-1.4M | $-174.4M | ||
| Q2 25 | $-893.1K | $-157.3M | ||
| Q1 25 | $-1.1M | $-115.8M | ||
| Q4 24 | $-1.9M | $-102.3M | ||
| Q3 24 | $-1.3M | $-80.4M | ||
| Q2 24 | — | $-70.8M | ||
| Q1 24 | — | $-68.9M |
毛利率LSHRNA
| Q4 25 | 27.2% | — | ||
| Q3 25 | 18.2% | — | ||
| Q2 25 | 26.7% | — | ||
| Q1 25 | 18.8% | — | ||
| Q4 24 | -1.2% | — | ||
| Q3 24 | 12.8% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
营业利润率LSHRNA
| Q4 25 | -21.3% | — | ||
| Q3 25 | -20.8% | -1513.5% | ||
| Q2 25 | -8.9% | -4448.7% | ||
| Q1 25 | -28.2% | -8360.9% | ||
| Q4 24 | -55.6% | -4069.6% | ||
| Q3 24 | -32.5% | -4200.9% | ||
| Q2 24 | — | -4040.4% | ||
| Q1 24 | — | -2178.6% |
净利率LSHRNA
| Q4 25 | -22.6% | — | ||
| Q3 25 | -22.2% | -1398.3% | ||
| Q2 25 | -14.2% | -4089.3% | ||
| Q1 25 | -28.2% | -7360.0% | ||
| Q4 24 | -54.1% | -3439.5% | ||
| Q3 24 | -32.7% | -3441.7% | ||
| Q2 24 | — | -3461.8% | ||
| Q1 24 | — | -1943.4% |
每股收益（稀释后）LSHRNA
| Q4 25 | $-0.08 | — | ||
| Q3 25 | $-0.09 | $-1.27 | ||
| Q2 25 | $-0.11 | $-1.21 | ||
| Q1 25 | $-0.14 | $-0.90 | ||
| Q4 24 | $-0.26 | $-0.80 | ||
| Q3 24 | $-0.18 | $-0.65 | ||
| Q2 24 | — | $-0.65 | ||
| Q1 24 | — | $-0.79 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.6M | $350.2M |
| 总债务越低越好 | $2.4M | — |
| 股东权益账面价值 | $12.2M | $1.9B |
| 总资产 | $24.3M | $2.1B |
| 负债/权益比越低杠杆越低 | 0.20× | — |
8季度趋势，按日历期对齐
现金及短期投资LSHRNA
| Q4 25 | $1.6M | — | ||
| Q3 25 | $4.5M | $350.2M | ||
| Q2 25 | $5.0M | $243.9M | ||
| Q1 25 | $1.5M | $254.2M | ||
| Q4 24 | $1.1M | $219.9M | ||
| Q3 24 | $2.7M | $370.2M | ||
| Q2 24 | — | $575.8M | ||
| Q1 24 | — | $471.4M |
总债务LSHRNA
| Q4 25 | $2.4M | — | ||
| Q3 25 | $2.4M | — | ||
| Q2 25 | $1.4M | — | ||
| Q1 25 | $774.2K | — | ||
| Q4 24 | $784.8K | — | ||
| Q3 24 | $589.9K | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益LSHRNA
| Q4 25 | $12.2M | — | ||
| Q3 25 | $7.0M | $1.9B | ||
| Q2 25 | $2.8M | $1.2B | ||
| Q1 25 | $749.8K | $1.3B | ||
| Q4 24 | $1.6M | $1.4B | ||
| Q3 24 | $3.6M | $1.5B | ||
| Q2 24 | — | $1.2B | ||
| Q1 24 | — | $830.9M |
总资产LSHRNA
| Q4 25 | $24.3M | — | ||
| Q3 25 | $18.6M | $2.1B | ||
| Q2 25 | $14.4M | $1.4B | ||
| Q1 25 | $9.9M | $1.5B | ||
| Q4 24 | $9.8M | $1.6B | ||
| Q3 24 | $10.8M | $1.6B | ||
| Q2 24 | — | $1.3B | ||
| Q1 24 | — | $951.5M |
负债/权益比LSHRNA
| Q4 25 | 0.20× | — | ||
| Q3 25 | 0.35× | — | ||
| Q2 25 | 0.48× | — | ||
| Q1 25 | 1.03× | — | ||
| Q4 24 | 0.48× | — | ||
| Q3 24 | 0.16× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-453.5K | $-156.2M |
| 自由现金流经营现金流 - 资本支出 | — | $-156.9M |
| 自由现金流率自由现金流/营收 | — | -1257.6% |
| 资本支出强度资本支出/营收 | — | 5.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-592.3M |
8季度趋势，按日历期对齐
经营现金流LSHRNA
| Q4 25 | $-453.5K | — | ||
| Q3 25 | $-4.0M | $-156.2M | ||
| Q2 25 | $-483.7K | $-199.7M | ||
| Q1 25 | $-238.3K | $-124.8M | ||
| Q4 24 | $-530.2K | $-99.9M | ||
| Q3 24 | $-1.4M | $-65.6M | ||
| Q2 24 | — | $-65.0M | ||
| Q1 24 | — | $-70.4M |
自由现金流LSHRNA
| Q4 25 | — | — | ||
| Q3 25 | — | $-156.9M | ||
| Q2 25 | $-497.4K | $-203.0M | ||
| Q1 25 | — | $-128.6M | ||
| Q4 24 | $-560.5K | $-103.8M | ||
| Q3 24 | $-1.4M | $-67.3M | ||
| Q2 24 | — | $-65.5M | ||
| Q1 24 | — | $-71.3M |
自由现金流率LSHRNA
| Q4 25 | — | — | ||
| Q3 25 | — | -1257.6% | ||
| Q2 25 | -7.9% | -5277.1% | ||
| Q1 25 | — | -8174.3% | ||
| Q4 24 | -15.6% | -3491.0% | ||
| Q3 24 | -34.5% | -2881.8% | ||
| Q2 24 | — | -3204.6% | ||
| Q1 24 | — | -2012.3% |
资本支出强度LSHRNA
| Q4 25 | — | — | ||
| Q3 25 | — | 5.7% | ||
| Q2 25 | 0.2% | 86.9% | ||
| Q1 25 | 0.0% | 238.6% | ||
| Q4 24 | 0.8% | 131.7% | ||
| Q3 24 | 0.1% | 72.9% | ||
| Q2 24 | — | 26.0% | ||
| Q1 24 | — | 25.8% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LSH
| Transferred Over Time | $4.6M | 65% |
| Distribution Of Pharmaceutical Products | $2.4M | 35% |
RNA
暂无分部数据
